NCT03291444

A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic Syndromes

Study Summary

The main purpose of this study is to verify the safety and potential effectiveness of CART cells combined with peptide specific dendritic cell in relapsed/refractory leukemia.

Want to learn more about this trial?

Request More Info

Interventions

Chimeric antigen receptor T cellsBIOLOGICAL
After pretreatment, chimeric antigen receptor T cells will be transfused.
peptide specific dendritic cellBIOLOGICAL
After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.

Study Locations

FacilityCityStateCountry
Zhujiang Hospital, Southern Medical UniversityGuangzhouGuangdongChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026